CytomX Therapeutics (CTMX) Reports In-Line Q2 EPS

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $18.11 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
• Catalyst Metals Ltd (CYL:AU) PT Lowered to AUD9.25 at UBS